Study Title
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Details
Description:
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Sponsor:
Memorial Sloan Kettering Cancer Center
Contacts:
Michael Morris, MD (Principal Investigator)morrism@mskcc.org
646-422-4469
Josef Fox, MD212-639-7371
Government Study Link:
NCT03574571 - Click here to see study onClinicalTrials.gov
© 2021 XCancer Software LLC
Contact XCancer: 402-991-8468